XML 29 R9.htm IDEA: XBRL DOCUMENT v3.25.0.1
Consolidated Statements Of Shareholders' Equity - USD ($)
$ in Thousands
Total
Common Stock
Retained Earnings
Trust for Savings Restoration Plan
Accumulated Other Comprehensive Income (Loss)
Foreign Currency Translation
Accumulated Net Gain (Loss) from Cash Flow Hedges Attributable to Parent [Member]
Beginning balance (in shares) at Dec. 31, 2021   33,736,629          
Beginning balance at Dec. 31, 2021 $ 184,722 $ 55,174 $ 281,187 $ (2,135) $ (149,504) $ (85,792) $ 901
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Net income (loss) 28,455   28,455        
Foreign currency translation adjustment (287)         (287)  
Derivative financial instruments adjustment (3,381)           (3,381)
Net gains or (losses) and prior service costs (5,064)       (5,064)    
Amortization of prior service costs and net gains or losses 10,641       10,641    
Recognition in earnings of actuarial loss for pension settlement (net of tax expense of $41,294 ) 0            
Cash dividends declared (16,974)   (16,974)        
Stock-based compensation expense (in shares)   294,764          
Stock-based compensation expense 4,046 $ 4,046          
Repurchase of employee common stock for tax withholdings (in shares)   (30,751)          
Repurchase of employee common stock for tax withholdings (396) $ (396)          
Tredegar common stock purchased by trust for savings restoration plan 0   53 (53)      
Ending balance (in shares) at Dec. 31, 2022   34,000,642          
Ending balance at Dec. 31, 2022 201,762 $ 58,824 292,721 (2,188) (147,595) (86,079) (2,480)
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Reclassification Adjustment from AOCI, Realized upon Sale or Liquidation, Net of Tax 0         0  
Reclassification of derivative financial instruments loss realized on the sale of Terphane (net of tax benefit $1,209) 0            
Net income (loss) (105,905)   (105,905)        
Foreign currency translation adjustment 3,042         3,042  
Derivative financial instruments adjustment 3,281           3,281
Net gains or (losses) and prior service costs 1,513       1,513    
Amortization of prior service costs and net gains or losses 7,065       7,065    
Recognition in earnings of actuarial loss for pension settlement (net of tax expense of $41,294 ) 50,997       50,997    
Cash dividends declared (8,884)   (8,884)        
Stock-based compensation expense (in shares)   407,996          
Stock-based compensation expense 3,036 $ 3,036          
Repurchase of employee common stock for tax withholdings (in shares)   0          
Repurchase of employee common stock for tax withholdings (254) $ (254)          
Tredegar common stock purchased by trust for savings restoration plan 0   45 (45)      
Ending balance (in shares) at Dec. 31, 2023   34,408,638          
Ending balance at Dec. 31, 2023 155,653 $ 61,606 177,977 (2,233) (81,697) (83,037) 801
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Reclassification Adjustment from AOCI, Realized upon Sale or Liquidation, Net of Tax 0         0  
Reclassification of derivative financial instruments loss realized on the sale of Terphane (net of tax benefit $1,209) 0            
Net income (loss) (64,565)   (64,565)        
Foreign currency translation adjustment (295)         (295)  
Derivative financial instruments adjustment 755           755
Net gains or (losses) and prior service costs 397            
Amortization of prior service costs and net gains or losses (110)       (110)    
Recognition in earnings of actuarial loss for pension settlement (net of tax expense of $41,294 ) 0            
Stock-based compensation expense (in shares)   252,634          
Stock-based compensation expense 2,211 $ 2,211          
Repurchase of employee common stock for tax withholdings (in shares)   0          
Repurchase of employee common stock for tax withholdings (227) $ (227)          
Ending balance (in shares) at Dec. 31, 2024   34,661,272          
Ending balance at Dec. 31, 2024 180,968 $ 63,590 $ 113,412 $ (2,233) $ 6,199 5,105 268
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Reclassification Adjustment from AOCI, Realized upon Sale or Liquidation, Net of Tax 88,437         $ 88,437  
Reclassification of derivative financial instruments loss realized on the sale of Terphane (net of tax benefit $1,209) $ (1,288)           $ (1,288)